Bao Guangfa, Tang Ming, Zhao Jun, Zhu Xiaohua
Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, China.
Department of Anatomy, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, China.
EJNMMI Res. 2021 Jan 19;11(1):6. doi: 10.1186/s13550-021-00750-5.
Nanobodies are the recombinant variable domains of heavy-chain-only antibodies, with many unique properties such as small size, excellent solubility, superior stability, quick clearance from blood, and deep tissue penetration. As a result, nanobodies have become a promising tool for the diagnosis and therapy of diseases. As imaging tracers, nanobodies allow an early acquisition of high-quality images, provide a comprehensive evaluation of the disease, and subsequently enable a personalized precision therapy. As therapeutic agents, nanobodies enable a targeted therapy by lesion-specific delivery of drugs and effector domains, thereby improving the specificity and efficacy of the therapy. Up to date, a wide variety of nanobodies have been developed for a broad range of molecular targets and have played a significant role in patients with a broad spectrum of diseases. In this review, we aim to outline the current state-of-the-art research on the nanobodies for medical applications and then discuss the challenges and strategies for their further clinical translation.
纳米抗体是仅重链抗体的重组可变结构域,具有许多独特特性,如尺寸小、溶解性优异、稳定性卓越、能快速从血液中清除以及可深入组织。因此,纳米抗体已成为疾病诊断和治疗的一种有前景的工具。作为成像示踪剂,纳米抗体能够早期获取高质量图像,对疾病进行全面评估,进而实现个性化精准治疗。作为治疗剂,纳米抗体可通过将药物和效应结构域特异性递送至病变部位实现靶向治疗,从而提高治疗的特异性和疗效。到目前为止,已针对广泛的分子靶点开发了各种各样的纳米抗体,并在患有多种疾病的患者中发挥了重要作用。在本综述中,我们旨在概述纳米抗体在医学应用方面的当前前沿研究,然后讨论其进一步临床转化面临的挑战和策略。